Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Local doctors in Cincinnati are preparing to launch a groundbreaking clinical trial that could revolutionize treatment for ...

As of H1 2024, 62% of the firm’s revenue came from its portfolio of drugs targeting multiple sclerosis. Within this portfolio ...

Through research in the Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic is leading scientific advances in multiple sclerosis treatment.

A large majority of RRMS patients experienced no evidence of disease activity for up to six years on Tysabri, a real-world ...

On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS ...

Today, Benzinga 's options scanner spotted 9 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 22% bullish and 66%, bearish. Out ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by equities research analysts at Needham & Company LLC from a “buy” ...

Fintel reports that on November 18, 2024, Needham downgraded their outlook for Biogen (NasdaqGS:BIIB) from Buy to Hold.

We recently published a list of 10 Cheap NASDAQ Stocks To Invest In Now. In this article, we are going to take a look at ...

It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of ...